Premium
Isosorbide‐5‐mononitrate in angina pectoris: Plasma concentrations and duration of effects after acute therapy
Author(s) -
Thadani Udho,
Prasad Rajesh,
Hamilton Stephen F,
Voyles Wyatt F,
Doyle Ralph,
Karpow Serge A,
Reder Robert,
Teague Stephen M
Publication year - 1987
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1987.108
Subject(s) - placebo , medicine , isosorbide mononitrate , angina , crossover study , oral administration , anesthesia , myocardial infarction , alternative medicine , pathology
In a double‐blind, randomized, crossover study, the duration of effects of single oral doses of 20 and 40 mg isosorbide‐5‐mononitrate (IS‐5MN) and matching placebo were studied in 12 male patients with angina pectoris. Plasma IS‐5MN concentrations (mean ± SD) 2 and 6 hours after administration were 300 ± 60 and 144 ± 43 ng/ml after 20 mg IS‐5MN and 551 ± 191 and 376 ± 129 ng/ml after 40 mg IS‐5MN. Exercise time to the onset of angina 2 and 6 hours after administration increased after 20 mg IS‐5MN (5.88 ± 1.85; P < 0.001 and 5.08 ± 1.97 minutes; P < 0.002) and 40 mg IS‐5MN (6.17 ± 1.88; P < 0.001 and 5.78 ± 1.72 minutes; P < 0.001) in comparison to placebo (4.57 ± 1.22 and 4.15 ± 1.22 minutes). Similarly, total exercise duration increased at 2 (P < 0.001) and 6 hours (P < 0.002) after both doses of IS‐5MN. Compared with placebo, ECG ST segment depression during exercise was less (P < 0.05) 2 hours after both doses of IS‐5MN. Thus single oral doses of 20 and 40 mg IS‐5MN exert antianginal and anti‐ischemic effects for at least up to 6 hours. Clinical Pharmacology and Therapeutics (1987) 42, 58–65; doi: 10.1038/clpt.1987.108